Pramodini Medicare has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI), marking its initial step towards a public listing. The company aims to raise capital through an issue with a maximum size of ₹500000. This move is significant for investors looking to participate in the early stages of the company's growth journey.

Company Overview

Pramodini Medicare operates in the healthcare sector, providing medical services and solutions. While specific operational details are pending further disclosure in the final prospectus, the company's entry into the public market highlights its strategic intent to expand its footprint and enhance its service capabilities.

Offer Details

The IPO structure includes a defined price band and issue size, providing clarity on the valuation range for potential investors.

The objects of the issue typically include funding working capital, expansion projects, and general corporate purposes, as detailed in the DRHP. The timeline for the IPO opening and closing dates will be confirmed closer to the launch.

Financial Highlights

Specific financial metrics such as revenue trends, profit margins, and key ratios are not yet available in the provided data. Investors should refer to the full DRHP document filed with SEBI for comprehensive financial statements covering the last two to three years.

Risk Factors

As with any IPO, investors must consider material risks associated with Pramodini Medicare. These may include regulatory changes in the healthcare sector, competition from established players, and execution risks related to business expansion. Detailed risk factors are outlined in the DRHP.

Valuation & Peer Comparison

With the price band set between ₹110.00000 and ₹118.00000, the implied valuation can be compared against peers in the healthcare sector once financial results are fully disclosed. Current subscription data shows 0 x across QIB, Retail, and Non-Institutional categories, indicating that the issue has not yet opened for subscription.

Bottom Line

Pramodini Medicare’s IPO represents an opportunity for investors to gain exposure to the healthcare sector. With a maximum issue size of ₹500000 and a price band of ₹110-118, the offering awaits further details on financial performance and risk factors in the final prospectus. Investors should monitor the SEBI website for updates on the IPO timeline and allotment status.

Pramodini Medicare Limited, a technology-enabled diagnostic services provider headquartered in Vijayawada, Andhra Pradesh, has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI). The company, incorporated in 2000, operates 16 diagnostic centres across 7 states and 14 cities, offering radiology, clinical laboratory, and nuclear medicine services. This IPO marks a significant step for the firm as it seeks to expand its network through capital expenditure and strategic acquisitions.

Company Overview

Pramodini Medicare provides diagnostic services to public hospitals, private hospitals, Public Sector Undertakings (PSUs), and medical colleges across tier I, II, and III cities in India. The company leverages four distinct business models to serve its diverse client base:

• Public Private Partnership (PPP): 7 centres operating under government arrangements.
• Private Private Partnership: 3 centres partnered with private healthcare entities.
• Strategic Partnership with PSUs: 4 centres tied up with Public Sector Undertakings.
• Private Centres: 2 independently operated diagnostic centres.

The company’s infrastructure includes 8 CT machines, 7 MRI machines, 20 X-ray machines, and 1 PET CT unit. Its revenue is diversified across B2G (61.46%), B2B (20.82%), and B2C (17.72%) segments, with radiology services contributing 97.05% of FY2026 revenue.

Offer Details

The IPO is structured as a fresh issue with no Offer for Sale (OFS). The price band has not been disclosed in the current DRHP data.

Objects of the Issue

The proceeds from the ₹45.15 crore fresh issue will be utilized for:

1. Funding Capital Expenditure: Purchase and installation of medical equipment at existing centres in Hubli, Manjeri, and Vijayawada, and establishment of a new diagnostic centre in Bangalore.
2. General Corporate Purposes: Evaluating inorganic growth opportunities through mergers and acquisitions, expanding into new geographies, and meeting general corporate expenses.

IPO Timeline

Financial Highlights

Pramodini Medicare has demonstrated strong revenue and profit growth over the last three fiscal years. Revenue from operations jumped by 62.89% YoY in FY2026, while PAT grew by 57.57% YoY.

Key profitability metrics for FY2026 include an EBITDA margin of 49.61% and a PAT margin on operations revenue of 27.90%. The Return on Equity (ROE) stood at 32.70% in FY2026.

Risk Factors

Investors should note several material risks disclosed in the DRHP:

1. Dependence on Government PPP Arrangements: 54.19% of revenue is derived from PPP arrangements with government authorities. Non-renewal or termination of MOUs could materially impact operations.
2. Heavy Concentration on Radiology Services: Radiology services account for 97.05% of FY2025-26 revenue, creating significant exposure to capital-intensive equipment requirements and regulatory compliance risks in this single domain.
3. Geographic Revenue Concentration: 61.90% of FY2025-26 revenue is derived from Andhra Pradesh, exposing the company to regional economic or political risks.
4. Customer Concentration: The top customer contributed 44.17% of FY2025-26 revenue, while the top 10 customers accounted for 64.83% of total revenue.
5. High Dependence on Government Revenue (B2G): B2G revenue constitutes 61.46% of total revenue, making the company vulnerable to changes in government policies and budget allocations.

Valuation & Peer Comparison

As the price band is not yet disclosed, formal valuation multiples such as P/E and P/B cannot be calculated. However, the company’s high EBITDA margin of 49.61% and strong ROE of 32.70% suggest a quality business profile. Investors may compare these metrics against listed peers like Krsnaa Diagnostics, which also operates a PPP-heavy model, once pricing details are available.

Bottom Line

Pramodini Medicare presents a high-growth diagnostic business with strong profitability margins and a diversified operational model across PPP, private partnerships, and direct centres. The filing of the DRHP indicates the company’s readiness to raise capital for expansion, particularly in Bangalore and existing hubs. However, investors must carefully weigh the extreme concentration risks in radiology services, geographic reliance on Andhra Pradesh, and dependency on government contracts before making investment decisions. The final verdict will depend heavily on the price band disclosure and valuation relative to peers.